I. To determine the maximum tolerated dose (MTD) of the combination of navitoclax and sorafenib tosylate (sorafenib) in patients with advanced solid tumors. (Dose escalation cohort) II. To better characterize the toxicity profile of the combination of navitoclax and sorafenib. (Dose expansion cohort) III. To identify any activity of this treatment combination in patients with metastatic cancer. (Dose escalation cohort) IV. To seek preliminary evidence of activity of this treatment combination in patients with hepatoma. (Dose expansion cohort)